drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Anti-CD33 antibody-drug conjugate that delivers calicheamicin; added to first induction in CD33-positive AML.
nci_thesaurus_concept_id
C1806
nci_thesaurus_preferred_term
Gemtuzumab Ozogamicin
nci_thesaurus_definition
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)
drug_mesh_term
Gemtuzumab Ozogamicin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-CD33 monoclonal antibody linked to calicheamicin; binds CD33 on leukemic blasts, is internalized, and releases calicheamicin that binds the DNA minor groove causing double-strand breaks, inhibition of DNA synthesis, and apoptosis.
drug_name
Gemtuzumab ozogamicin
nct_id_drug_ref
NCT05994690